SNSE Sensei Bio: Enterprise Value-to-Revenue Multiple

Public company logo of Sensei Biotherapeutics Inc (SNSE)

Is the investment attractiveness of Sensei Biotherapeutics (SNSE), which develops advanced vaccines to train the immune system to fight tumors, compelling? The EV/Sales trend on this GURU.Markets platform chart, where the value is fixed at 0.00, provides the answer. The business is highly resilient to crises during the R&D stage, as saving lives remains a priority. The company's growth relies on the success of clinical trials and the commercialization of its products.

Company Value to Revenue: Sensei Bio (SNSE) for 11/23/2025 - 06/16/2026

Sensei Bio - analytical breakdowns and key metrics (SNSE)

- share price and consensus valuation forecast:
Initial company analysis:Sensei Biotherapeutics Inc SNSE
Product sample of Sensei Biotherapeutics Inc

The innovative ImmunoPhage platform provides Sensei Biotherapeutics (SNSE) with a competitive advantage in developing targeted vaccines against resistant tumors. The company's enterprise value-to-revenue metric quantifies this potential by comparing the total business value net of debt against sales volume, allowing investors to assess real capitalization per unit of revenue and determine the asset's true trend on this chart.

Competitor analysis for Sensei Biotherapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP